Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3C-like proteinase (3CLpro), also known as the main protease (Mpro) or non-structural protein 5 (nsp5), is an essential enzyme for the replication of the SARS-associated coronavirus (SARS-CoV) [1, 14]. It is a cysteine protease that functions as a homodimer, utilizing a catalytic dyad of Cys145 and His41 to cleave the large viral polyproteins, pp1a and pp1ab, at eleven specific sites [4, 14]. This proteolytic processing is required to release functional non-structural proteins that form the viral replicase-transcriptase complex [10, 12]. Because 3CLpro has a unique substrate specificity—cleaving after a glutamine residue—and no known human proteases share this requirement, it is a highly attractive and selective target for antiviral therapy [1, 2]. Drugs targeting this enzyme, such as nirmatrelvir and various peptidomimetics, act by binding to the active site and inhibiting its catalytic activity, thereby halting the production of infectious virus particles [8, 10]. In addition to its role in replication, 3CLpro has been implicated in antagonizing the host's innate immune response by degrading key signaling proteins like IRF3 [15]. Consequently, 3CLpro inhibitors not only reduce viral load but may also help restore host immune defenses during infection [10, 15].
Inhibition of the catalytic activity of the protease by binding to the active site (Cys145/His41 dyad), preventing the cleavage of viral polyproteins pp1a and pp1ab into functional non-structural proteins.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3C-like proteinase (3CLpro) (3CLpro).